Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 3Pancreatic Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Malignant Neoplasms of Digestive Organs 1Klatskin Tumor 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 12Cisplatin 10pembrolizumab 7Fluorouracil 7Leucovorin 6Oxaliplatin 5durvalumab 3Capecitabine 3zanidatamab 2Paclitaxel 2Irinotecan 2Folfox protocol 2Bevacizumab 2vandetanib 1tucatinib 1trastuzumab deruxtecan 1seribantumab 1merestinib 1lenvatinib 1irinotecan sucrosofate 1galactomannan 1fludarabine 1exatecan 1bintrafusp alfa protein, human 1becatecarin 1aldesleukin 1Trastuzumab 1Temozolomide 1Tegafur 1S 1 (combination) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gallbladder Neoplasms × Tegafur × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡